Video
Dr. Efstathiou on safety of niraparib/abiraterone in mCRPC
Author(s):
The toxicity profile was consistent with the first interim analysis of the phase 3 MAGNITUDE study with no new safety signals observed.
Eleni Efstathiou, MD, PhD, medical oncologist, and section chief of Genitourinary Medical Oncology at Houston Methodist Cancer Center in Texas, discusses safety data from the second interim analysis of the phase 3 MAGNITUDE study (NCT03748641), which she presented at the 2023 Genitourinary Cancers Symposium.
The study compared niraparib (Zejula) plus abiraterone acetate (Zytiga) and prednisone versus abiraterone and prednisone alone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations.
The toxicity profile was consistent with the first interim analysis, and no new safety signals were observed. Adverse effects (AEs) were generally more common among patients treated with niraparib. The most frequent AEs in the niraparib and placebo groups were anemia (50.0% vs 22.7%), hypertension (33.0% vs 22.3%), and constipation (33.0% vs 15.6%).
